Rosalind Study & Cure51 Patients' Committee
Help shape a study
The project
Cure51 is revolutionizing cancer research by creating the world’s first global clinical and molecular database of long-term cancer survivors. By studying these exceptional “outliers” who have beaten highly lethal cancers against all odds, the company aims to decode the biological mechanisms behind their remarkable survival.
Their research meticulously analyses genetic, immunological, and clinical data to identify new therapeutic targets. The ultimate goal is to translate this knowledge into innovative, first-in-class treatments, using the blueprint of exceptional survival to develop new drugs that can help a wider patient population
What are you going to do?
Cure51 will build a large collection of multimodal data from exceptional survivors and matching controls. Why: To identify biomarkers of resistance and/or survival which would help identify new therapeutic targets. How: High precision molecular analysis based on state-of-the-art sequencing.
Why is this research important?
The Rosalind study includes Pancreatic Cancers (mPDAC) long term survivors. It is a true message of hope for patients who received this bad diagnosis. By understanding the biological reasons these “outliers” survive, Cure51 can identify new drug targets and develop “first-in-class” treatments. This approach offers a new path to create transformative therapies for pancreatic cancer patients, potentially increasing their survival chances.
How to get involved
The Patients Committee is actively seeking partners to help us with this project! They’re looking for individuals with lived experience who are interested in collaborating on new initiatives.
Their goal is to create opportunities that bring hope to the pancreatic cancer community and allow them to connect with new, inspiring people. They are flexible and want to discuss how they can work together to achieve their shared objectives, such as by participating in webinars, patient talks, or summits.
They have a lot to offer, including insights from their PDAC survivors study and community of patients. They also have experience with patient interviews, social media outreach, creating patient content, and organizing events. They are happy to tailor the involvement to fit your availability.
Events and meetings will be held virtually.
No scientific background or prior experience is needed to take part in this opportunity.
Next steps
If you are interested in getting involved or would like more information, please email Yann Bizien (yann.bizien@cure51.com) quoting the involvement reference ‘RIN Patient group’.
